Scimar’s operations are supported by our investors. Since launching our seed round in 2018, we’ve attracted over $13 million in private investments from more than 75 investors.
In mid-2021, we launched our Series A round to build infrastructure, accelerate our research and clinical trials, and support our subsequent market launches of SciMar NuPa Daily: a nutraceutical designed to protect hepatalin production.
- No other research group in the world is studying the hepatalin hormone discovered by Dr. W. Wayne Lautt. Hepatalin is at the centre of our discoveries.
- Nearly half a billion people worldwide live with type 2 diabetes. Many millions more have prediabetes. Scimar’s product suite is poised to make a transformational difference in the prevention, diagnosis, and treatment of type 2 diabetes.
- Our product pipeline is protected by patents.
- Scimar’s research team is working toward producing a large enough physical sample of pure natural hepatalin to satisfy the terms of any material transfer agreement with a pharmaceutical company. We are less than a gram away.
|Public funds, grants, and incubator investments (attracted by Dr. Lautt while working as an academic):||$17.3 million|
|Seed round, 2018–2021:||$9.5 million|
|Bridge round, 2021:||$3.5 million in preferred convertible shares|
|Series A round, 2022:||$3.7 million|
*All funds expressed in Canadian dollars